[
  {
    "ts": null,
    "headline": "Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn",
    "summary": "On Thursday, Moderna Inc. (NASDAQ:MRNA) reported third-quarter revenue of $1.83 billion, beating the consensus of $1.25 billion. The company attributed the growth to higher sales in the U.S. market following the earlier launch of the updated COVID-19 vaccine. BofA Securities notes that Moderna’s stock rose early Thursday but ended the day lower, likely due to slowing vaccine trends and uncertainty around the company’s respiratory vaccine lineup, as well as new concerns related to Trump and Kenne",
    "url": "https://finnhub.io/api/news?id=af06a91d98ae9facf0b08ca6cd4464e2d4d35dfaf9bc639965955b8240ab1d20",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731091679,
      "headline": "Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn",
      "id": 131229414,
      "image": "https://media.zenfs.com/en/Benzinga/83154044d5195ec15261147af3841369",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "On Thursday, Moderna Inc. (NASDAQ:MRNA) reported third-quarter revenue of $1.83 billion, beating the consensus of $1.25 billion. The company attributed the growth to higher sales in the U.S. market following the earlier launch of the updated COVID-19 vaccine. BofA Securities notes that Moderna’s stock rose early Thursday but ended the day lower, likely due to slowing vaccine trends and uncertainty around the company’s respiratory vaccine lineup, as well as new concerns related to Trump and Kenne",
      "url": "https://finnhub.io/api/news?id=af06a91d98ae9facf0b08ca6cd4464e2d4d35dfaf9bc639965955b8240ab1d20"
    }
  },
  {
    "ts": null,
    "headline": "2 Biotech Stocks You Can Buy Hand Over Fist This Month",
    "summary": "Both stocks have made significant breakthroughs.",
    "url": "https://finnhub.io/api/news?id=703e5dd7d5c6f064e8bf46a7632f9362ef60b7cea15114ef1a69a603035c180e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731078000,
      "headline": "2 Biotech Stocks You Can Buy Hand Over Fist This Month",
      "id": 131223331,
      "image": "https://g.foolcdn.com/editorial/images/796648/pharmacist-talking-to-patient.jpg",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Both stocks have made significant breakthroughs.",
      "url": "https://finnhub.io/api/news?id=703e5dd7d5c6f064e8bf46a7632f9362ef60b7cea15114ef1a69a603035c180e"
    }
  },
  {
    "ts": null,
    "headline": "Moderna : SITC INT Phase 1 Trial Design",
    "summary": "Poster Number A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of ...",
    "url": "https://finnhub.io/api/news?id=b35438bd1882ad3cc12c2e5cfa5336d56b00238b83b0ed98256b760a64d9a98d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731077106,
      "headline": "Moderna : SITC INT Phase 1 Trial Design",
      "id": 131227788,
      "image": "",
      "related": "MRNA",
      "source": "Finnhub",
      "summary": "Poster Number A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of ...",
      "url": "https://finnhub.io/api/news?id=b35438bd1882ad3cc12c2e5cfa5336d56b00238b83b0ed98256b760a64d9a98d"
    }
  },
  {
    "ts": null,
    "headline": "Moderna (MRNA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates",
    "summary": "Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
    "url": "https://finnhub.io/api/news?id=ec617a892e45411e28379999e442ab492c2f6cb36669561b681197e390abbb94",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731076211,
      "headline": "Moderna (MRNA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates",
      "id": 131223332,
      "image": "https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
      "url": "https://finnhub.io/api/news?id=ec617a892e45411e28379999e442ab492c2f6cb36669561b681197e390abbb94"
    }
  },
  {
    "ts": null,
    "headline": "Moderna : SITC INT Phase 1 Trial Description",
    "summary": "A Phase 1 Study to Test the Safety and Effectiveness of mRNA-4157 for Patients with Solid Tumors BACKGROUND ...",
    "url": "https://finnhub.io/api/news?id=8017b11e817610d99519bfc0f155b77e4864e5a2bd5729353e617e5e8ce057ed",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731075878,
      "headline": "Moderna : SITC INT Phase 1 Trial Description",
      "id": 131227567,
      "image": "",
      "related": "MRNA",
      "source": "Finnhub",
      "summary": "A Phase 1 Study to Test the Safety and Effectiveness of mRNA-4157 for Patients with Solid Tumors BACKGROUND ...",
      "url": "https://finnhub.io/api/news?id=8017b11e817610d99519bfc0f155b77e4864e5a2bd5729353e617e5e8ce057ed"
    }
  },
  {
    "ts": null,
    "headline": "Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma",
    "summary": "Carisma Therapeutics Inc. (Nasdaq: CARM) (\"Carisma\" or the \"Company\"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, \"CAR-M\") therapy for hepatocellular carcinoma (\"HCC\"), developed in collaboration with Moderna, Inc. (Nasdaq: MRNA). The data demonstrated that the development candidate can successfully crea",
    "url": "https://finnhub.io/api/news?id=8e4b30c34e2f453a4151c4ed0c4fc23118758a7c329e90cc3a6e544f835f53a3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731069000,
      "headline": "Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma",
      "id": 131223336,
      "image": "https://media.zenfs.com/en/prnewswire.com/ffc8d7a6f9a8e6fb35c642709403ae67",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Carisma Therapeutics Inc. (Nasdaq: CARM) (\"Carisma\" or the \"Company\"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, \"CAR-M\") therapy for hepatocellular carcinoma (\"HCC\"), developed in collaboration with Moderna, Inc. (Nasdaq: MRNA). The data demonstrated that the development candidate can successfully crea",
      "url": "https://finnhub.io/api/news?id=8e4b30c34e2f453a4151c4ed0c4fc23118758a7c329e90cc3a6e544f835f53a3"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older",
    "summary": "mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA following approvals in the U.S., Europe, and Qatar ...",
    "url": "https://finnhub.io/api/news?id=786fefdd0bf46cc239831f29a72ef38bab969a36de8eb977a8b803d6c2ad74db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731069000,
      "headline": "Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older",
      "id": 131223334,
      "image": "https://media.zenfs.com/en/accesswire.ca/2233b456baebcb9b5dcb57d6eaa868ac",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA following approvals in the U.S., Europe, and Qatar ...",
      "url": "https://finnhub.io/api/news?id=786fefdd0bf46cc239831f29a72ef38bab969a36de8eb977a8b803d6c2ad74db"
    }
  },
  {
    "ts": null,
    "headline": "Moderna: RSV vaccine approved in Canada for the over-60s",
    "summary": "Moderna announces that Health Canada has approved mRESVIA, its mRNA respiratory syncytial virus vaccine, for the prevention of lower respiratory tract infections in adults aged 60 and over. mRESVIA,...",
    "url": "https://finnhub.io/api/news?id=b7bacedfaba94d36813cb0416b695c90b29412af8f5c306670887e11cf6c5fc1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731062838,
      "headline": "Moderna: RSV vaccine approved in Canada for the over-60s",
      "id": 131219594,
      "image": "",
      "related": "MRNA",
      "source": "Finnhub",
      "summary": "Moderna announces that Health Canada has approved mRESVIA, its mRNA respiratory syncytial virus vaccine, for the prevention of lower respiratory tract infections in adults aged 60 and over. mRESVIA,...",
      "url": "https://finnhub.io/api/news?id=b7bacedfaba94d36813cb0416b695c90b29412af8f5c306670887e11cf6c5fc1"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Third Quarter 2024 Earnings: Beats Expectations",
    "summary": "Moderna ( NASDAQ:MRNA ) Third Quarter 2024 Results Key Financial Results Revenue: US$1.86b (up 1.7% from 3Q 2023). Net...",
    "url": "https://finnhub.io/api/news?id=d8adbf862033dabde94b4b7b6ba520addb95aa47beb9aba8c804e96bf9571dcf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731061827,
      "headline": "Moderna Third Quarter 2024 Earnings: Beats Expectations",
      "id": 131223337,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna ( NASDAQ:MRNA ) Third Quarter 2024 Results Key Financial Results Revenue: US$1.86b (up 1.7% from 3Q 2023). Net...",
      "url": "https://finnhub.io/api/news?id=d8adbf862033dabde94b4b7b6ba520addb95aa47beb9aba8c804e96bf9571dcf"
    }
  },
  {
    "ts": null,
    "headline": "Canada approves Moderna's RSV vaccine for adults aged 60 and older",
    "summary": "Moderna has received approval from Canada's health regulator for its respiratory syncytial virus vaccine in adults 60 years of age and older, the vaccine maker said on Friday. ...",
    "url": "https://finnhub.io/api/news?id=58199a2b4dd1574fd1bac934afdb82bb192ee977f339cc0b259b2dc41d1a8981",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731054183,
      "headline": "Canada approves Moderna's RSV vaccine for adults aged 60 and older",
      "id": 131216959,
      "image": "",
      "related": "MRNA",
      "source": "Finnhub",
      "summary": "Moderna has received approval from Canada's health regulator for its respiratory syncytial virus vaccine in adults 60 years of age and older, the vaccine maker said on Friday. ...",
      "url": "https://finnhub.io/api/news?id=58199a2b4dd1574fd1bac934afdb82bb192ee977f339cc0b259b2dc41d1a8981"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Inc (MRNA) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ...",
    "summary": "Moderna Inc (MRNA) reports $1.9 billion in revenue and outlines future growth strategies despite competitive pressures and legal challenges.",
    "url": "https://finnhub.io/api/news?id=b2f7ccba74f3e7e7c781f9444e7248594c7115f355912519b798a4ba93bfe8f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731049820,
      "headline": "Moderna Inc (MRNA) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ...",
      "id": 131194135,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/a08ca0be7a3c7eba532c79926311ae82",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna Inc (MRNA) reports $1.9 billion in revenue and outlines future growth strategies despite competitive pressures and legal challenges.",
      "url": "https://finnhub.io/api/news?id=b2f7ccba74f3e7e7c781f9444e7248594c7115f355912519b798a4ba93bfe8f3"
    }
  }
]